Here are 1-2 brief analogies for Rezolute (RZLT):

• Like a clinical-stage Vertex Pharmaceuticals, specializing in rare metabolic disorders.
• A developing Amgen that's zeroing in on new therapies for glucose imbalances.

• RZ358: A human monoclonal antibody in Phase 2b clinical trials for the treatment of congenital hyperinsulinism.
• RZ402: A selective and potent plasma kallikrein inhibitor in Phase 1 clinical trials for the chronic treatment of diabetic macular edema.

Rezolute, Inc. (RZLT) is a clinical-stage biopharmaceutical company focused on developing transformative therapies for metabolic diseases. As such, its product candidates (RZ358 and RZ402) are currently in clinical trials (Phase 2b and Phase 1, respectively) and are not yet approved or commercialized. Therefore, Rezolute does not currently have major customers from the sale of its products.

• Lonza Group AG (LONN)
• AGC Inc. (5201)
• Ajinomoto Co., Inc. (2802)
• Thermo Fisher Scientific Inc. (TMO)

Nevan Charles Elam, J.D. Chief Executive Officer & Founder

Nevan Charles Elam is the Co-Founder of Rezolute, which he started in January 2010, initially as AntriaBio. He possesses a diverse background spanning technology, law, and life sciences. Prior to Rezolute, he served as CEO of AeroSurgical Limited, a medical device company. He also directed the Pulmonary Business Unit of Nektar Therapeutics, which was acquired by Novartis in 2008. Mr. Elam was instrumental in spinning out two entities from Nektar, one of which was Pearl Therapeutics, later acquired by AstraZeneca for $1 billion in 2013. Earlier in his career, he co-founded and served as CFO of a web-based IT platform company. He was also a corporate partner at the law firm Wilson Sonsini Goodrich & Rosati, where he advised healthcare and technology companies and notably represented Steve Jobs' company, Next, negotiating its sale to Apple in 1997. He holds a J.D. from Harvard Law School and a B.A. from Howard University.

Daron Evans, M.S., M.B.A. Chief Financial and Business Officer

Daron Evans was appointed Chief Financial Officer of Rezolute in January 2024. He brings over 15 years of experience leading financial operations, investor relations, and business development for both public and private life science companies. Before joining Rezolute, Mr. Evans held CEO positions at AlloRock, Inc., a biotechnology company, and Specialty Renal Products, Inc., a medical device company. He also previously served as CEO of Nephros, Inc., and CFO of Nile Therapeutics, Inc. Since 2015, he has been the Managing Director of PoC Capital, LLC, a fund that invests in public life science companies. Mr. Evans earned a Bachelor of Science in Chemical Engineering from Rice University, a Master of Science in Biomedical Engineering, and an M.B.A. from the Fuqua School of Business at Duke University.

Brian Roberts, M.D. Chief Medical Officer

Brian Roberts serves as the Chief Medical Officer of Rezolute. His employment agreement was amended in October 2025.

Sunil Karnawat, Ph.D., M.B.A. Chief Commercial Officer

Sunil Karnawat was appointed Chief Commercial Officer of Rezolute in August 2025. He has over 25 years of experience in the global commercialization of biopharmaceuticals and medical devices, having launched products across various disease states, including ultra-rare bone and metabolic diseases, diabetes, obesity, and rheumatoid arthritis. Prior to Rezolute, he was a Vice President at Cytokinetics and Ultragenyx, where he was responsible for leading key commercial functions in the launch of four ultra-rare disease products. He also led Market Access teams at Myriad Genetics and Vivus Pharmaceuticals, and Analytics and Commercial Operations teams at Novo Nordisk for the U.S. launch of Victoza. Mr. Karnawat began his career at Deloitte Consulting. He holds an MBA from the Wharton School of Business, a Ph.D. and M.S. in Engineering, and a B.E. in Civil Engineering.

Michael R. Deperro Senior Vice President & Head of Operations

Michael R. Deperro is a founding management team member at Rezolute and serves as Senior Vice President & Head of Operations, while also maintaining his role as Head of Technical Operations. Before joining Rezolute, he was Vice President and General Manager at AntriaBio, the company's former name. His prior experience includes leading CDMO manufacturing operations at Agere Pharmaceuticals and Bend Research Inc., and Commercial and Clinical Manufacture at Alkermes Inc. He holds a Bachelor of Science in Mechanical Engineering from the University of Notre Dame.

The key risks for Rezolute, Inc. (RZLT), a clinical-stage biopharmaceutical company, primarily revolve around the inherent uncertainties of drug development and its financial implications.

1. Clinical Trial Failure and Regulatory Approval Risk: The most significant risk stems from the potential for its product candidates to fail in clinical trials or to not receive regulatory approval. Rezolute's lead product candidate, ersodetug (previously referred to as RZ358), recently failed its pivotal Phase 3 sunRIZE trial for congenital hyperinsulinism, missing both its primary and key secondary endpoints in December 2025. This setback led to a substantial decline in the company's share price and raised concerns about the viability of its clinical programs. As a clinical-stage entity, the company's future revenue generation and success are entirely contingent upon the successful development, clinical validation, and subsequent regulatory approval of its drug candidates, including RZ402, which is currently in Phase 1 clinical trials.

2. Funding and Capital Raise Risk: Rezolute has a history of losses and has not generated revenue in the trailing twelve months, reflecting its status as a clinical-stage company. Developing drugs through multiple clinical phases is an expensive and capital-intensive endeavor. The company experienced a notable reduction in its cash reserves, decreasing from $167.9 million to $132.9 million over the last six months of 2025. While Rezolute currently maintains strong liquidity, its ongoing losses and the recent Phase 3 trial failure underscore its continuous reliance on external funding to sustain operations and advance its pipeline. The inability to secure sufficient additional capital could significantly impede or halt its drug development programs.

The addressable markets for Rezolute's main products are as follows:

• RZ358 for Congenital Hyperinsulinism: The global congenital hyperinsulinism treatment market was valued at approximately USD 158.91 million in 2026, with projections to reach USD 223.66 million by 2031 at a CAGR of 7.08%. Another estimate placed the global market at USD 203.65 million in 2025, anticipated to grow to USD 302.41 million by 2032 with a CAGR of 5.81%. The North American market held a significant share, accounting for 61.3% of the revenue in 2022, and the United States alone represents approximately 40% of the overall congenital hyperinsulinism market size.
• RZ402 for Diabetic Macular Edema: The global diabetic macular edema (DME) market is a multi-billion dollar market. In 2024, it was valued at approximately USD 3.33 billion, and other estimates for 2025 range from USD 3.82 billion to USD 4.39 billion. The market is projected to reach around USD 4.34 billion by 2032 or up to USD 7.44 billion by 2033. North America is a leading region in the DME market, accounting for approximately 45% of the global market share, and is expected to maintain its dominance with a 39.7% share in 2024.

Rezolute (NASDAQ: RZLT) is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. While analyst forecasts indicate no revenue in 2026 and 2027, with an average of $55.9 million projected for 2028, the company's future revenue growth over the next 2-3 years is expected to be driven by key clinical development milestones and potential commercialization efforts for its lead product candidates.

Here are 3-5 expected drivers of future revenue growth for Rezolute:

1. Successful Completion and Positive Topline Data from the Phase 3 upLIFT Trial for RZ358 in Tumor Hyperinsulinism (tHI): Rezolute is currently conducting the Phase 3 upLIFT study for RZ358, its human monoclonal antibody, in patients with tumor hyperinsulinism. Topline results from this study are anticipated in the second half of 2026. Positive data from this trial would be a critical de-risking event, paving the way for regulatory submissions and eventual commercialization. The FDA has already agreed to a streamlined clinical development path for this study.
2. Regulatory Approval and Commercial Launch of RZ358 for Tumor Hyperinsulinism (tHI): Following successful topline data from the upLIFT trial in the second half of 2026, Rezolute could pursue a Biologics License Application (BLA) for RZ358 in tumor hyperinsulinism. If approved within the 2-3 year timeframe (e.g., late 2027 or early 2028), this would mark the company's first potential product launch and a direct source of revenue, aligning with analyst forecasts for revenue generation around 2028. Evidence from an Expanded Access Program for tumor HI patients showed RZ358 enabled 75% of patients to discontinue IV dextrose/TPN, suggesting potential efficacy.
3. Advancement of RZ402 through Clinical Development for Diabetic Macular Edema (DME): Rezolute is developing RZ402, an oral plasma kallikrein inhibitor, for the chronic treatment of diabetic macular edema. While currently in Phase 1 clinical trial, successful progression through this and subsequent clinical phases (e.g., initiation of a Phase 2 trial) would significantly increase the asset's value. The global diabetic macular edema market is projected to reach $7.5 billion by 2034, highlighting the substantial market opportunity for a novel oral therapy.
4. Strategic Partnership or Out-licensing of RZ402: Given the large potential market for RZ402 in DME, a strategic partnership or out-licensing agreement for this asset could be a significant driver of non-dilutive capital for Rezolute. Such a partnership could involve upfront payments, development milestones, and future royalties, providing an alternative or complementary revenue stream even if direct product sales are further in the future.

Share Issuance

• In April 2025, Rezolute completed an underwritten public offering of common stock and pre-funded warrants, generating approximately $96.9 million in net proceeds, including the full exercise of underwriters' option to purchase additional shares.
• In June 2024, the company raised approximately $60 million in net proceeds through a public offering of over 11 million shares and pre-funded warrants, which later increased to about $67 million in gross proceeds after the exercise of an over-allotment option. A concurrent private placement in June 2024 also issued 1,500,000 shares at $4.00 per share.
• In November 2025, stockholders approved an amendment to the 2021 Stock Incentive Plan, increasing the shares available for issuance from 14,450,000 to 21,950,000.

Inbound Investments

• The April 2025 offering included significant participation from institutional investors such as Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, Great Point Partners, Marshall Wace, Woodline Partners LP, Nantahala Capital, and Squadron Capital Management.
• In December 2025, RA Capital disclosed a 9.9% passive ownership stake in Rezolute.
• Throughout 2025, various institutional investors increased their holdings in Rezolute; for example, 22NW LP purchased 820,653 shares valued at approximately $7,714,000 in the third quarter, and Mangrove Partners IM LLC increased its stake to 2,882,149 shares worth approximately $27,092,000.

Capital Expenditures

• Rezolute has reported minimal to no capital expenditures over the last five years, with "Capital Expenditure (TTM)" indicated as null or 0%. This aligns with the company's focus as a clinical-stage biopharmaceutical entity.
• Research and development (R&D) expenses were $14.3 million for the second quarter of fiscal 2026, compared with $12.6 million for the same period a year prior, indicating that a significant portion of capital is allocated to R&D activities rather than traditional capital assets.